Ethyl formate → trans-N-(6,7-Dichloro-2,3,4,14b-tetrahydro-1H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)formamide
反応式
[Cl:1][C:2]1[C:12]2[N:11]3[CH2:13][CH2:14][CH2:15][C@@H:16]([NH:17]CCOC)[C@H:10]3[C:9]3[CH:22]=[CH:23][CH:24]=[CH:25][C:8]=3[O:7][C:6]=2[CH:5]=[CH:4][C:3]=1[Cl:26].[CH:27](OCC)=[O:28]>>[Cl:1][C:2]1[C:12]2[N:11]3[CH2:13][CH2:14][CH2:15][C@@H:16]([NH:17][CH:27]=[O:28])[C@H:10]3[C:9]3[CH:22]=[CH:23][CH:24]=[CH:25][C:8]=3[O:7][C:6]=2[CH:5]=[CH:4][C:3]=1[Cl:26]参加物
3
実験手順
A solution of trans-6,7-dichloro-2,3,4,14b-tetrahydro-N-(2-methoxyethyl)-1H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-amine (122 mg, 0.36 mmol) in ethyl formate was stirred overnight at reflux temperature. After removal of the solvent under reduced pressure, the remaining product was purified with preparative LC-MS to give the title compound (40 mg, 30%). Data (m/z)=397 (M+H)+.